Zakowski Maureen F, Rekhtman Natasha, Auger Manon, Booth Christine N, Crothers Barbara, Ghofrani Mohiddean, Khalbuss Walid, Laucirica Rodolfo, Moriarty Ann T, Tabatabai Z Laura, Barkan Güliz A
From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Drs Zakowski and Rekhtman); the Department of Pathology, Royal Victoria Hospital, Montreal, Quebec, Canada (Dr Auger); the Department of Pathology, Cleveland Clinic Main Campus, Cleveland, Ohio (Dr Booth); the Department of Pathology, Walter Reed Army Medical Center, Washington, DC (Dr Crothers); the Department of Pathology, Peacehealth Laboratory, Vancouver, Washington (Dr Ghofrani); the Department of Pathology, University of Pittsburgh Medical Center Shadyside, Pittsburgh, Pennsylvania (Dr Khalbuss); the Department of Pathology, Baylor College of Medicine, Houston, Texas (Dr Laucirica); the Department of Pathology, AmeriPath, Indianapolis, Indiana (Dr Moriarty); the Department of Pathology, University of California, San Francisco (Dr Tabatabai); and the Department of Pathology, Loyola University Medical Center, Maywood, Illinois (Dr Barkan). Dr Zakowski is no longer affiliated with Memorial Sloan Kettering Cancer Center. Dr Khalbuss is now with GE Clarient Diagnostic Services, Riyadh, Saudi Arabia. Dr Moriarty is no longer affiliated with AmeriPath.
Arch Pathol Lab Med. 2016 Oct;140(10):1116-20. doi: 10.5858/arpa.2015-0316-OA. Epub 2016 Aug 23.
-The National Cancer Care Network and the combined College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines indicate that all lung adenocarcinomas (ADCs) should be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. As the majority of patients present at a later stage, the subclassification and molecular analysis must be done on cytologic material.
-To evaluate the accuracy and interobserver variability among cytopathologists in subtyping non-small cell lung carcinoma using cytologic preparations.
-Nine cytopathologists from different institutions submitted cases of non-small cell lung carcinoma with surgical follow-up. Cases were independently, blindly reviewed by each cytopathologist. A diagnosis of ADC or squamous cell carcinoma was rendered based on the Diff-Quik, Papanicolaou, and hematoxylin-eosin stains. The specimen types included fine-needle aspiration from lung, lymph node, and bone; touch preparations from lung core biopsies; bronchial washings; and bronchial brushes. A major disagreement was defined as a case being misclassified 3 or more times.
-Ninety-three cases (69 ADC, 24 squamous cell carcinoma) were examined. Of 818 chances (93 cases × 9 cytopathologists) to correctly identify all the cases, 753 correct diagnoses were made (92% overall accuracy). Twenty-five of 69 cases of ADC (36%) and 7 of 24 cases of squamous cell carcinoma (29%) had disagreement (P = .16). Touch preparations were more frequently misdiagnosed compared with other specimens. Diagnostic accuracy of each cytopathologist varied from 78.4% to 98.7% (mean, 91.7%).
-Lung ADC can accurately be distinguished from squamous cell carcinoma by morphology in cytologic specimens with excellent interobserver concordance across multiple institutions and levels of cytology experience.
美国国立综合癌症网络以及美国病理学家学会/国际肺癌研究协会/分子病理学协会联合发布的指南指出,所有肺腺癌均应检测表皮生长因子受体(EGFR)突变和间变性淋巴瘤激酶(ALK)重排。由于大多数患者就诊时已处于晚期,因此必须对细胞学标本进行亚型分类和分子分析。
评估细胞病理学家使用细胞学标本对非小细胞肺癌进行亚型分类时的准确性和观察者间的变异性。
来自不同机构的9位细胞病理学家提交了有手术随访结果的非小细胞肺癌病例。每位细胞病理学家独立、盲法审查这些病例。根据Diff-Quik染色、巴氏染色和苏木精-伊红染色诊断为腺癌或鳞状细胞癌。标本类型包括经皮肺穿刺针吸活检、淋巴结和骨穿刺针吸活检;肺芯活检的印片;支气管灌洗;以及支气管刷检。主要分歧定义为一个病例被错误分类3次或更多次。
共检查了93例病例(69例腺癌,24例鳞状细胞癌)。在818次(93例×9位细胞病理学家)正确识别所有病例的机会中,做出了753次正确诊断(总体准确率为92%)。69例腺癌中有25例(36%)以及24例鳞状细胞癌中有7例(29%)存在分歧(P = 0.16)。与其他标本相比,印片更容易被误诊。每位细胞病理学家的诊断准确率在78.4%至98.7%之间(平均为91.7%)。
在多个机构以及不同细胞学经验水平的观察者之间,细胞学标本中的肺腺癌可通过形态学与鳞状细胞癌准确区分,观察者间一致性良好。